Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Epizyme, Inc. (EPZM : NSDQ)
 
 • Company Description   
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.

Number of Employees: 250

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.50 Daily Weekly Monthly
20 Day Moving Average: 1,715,005 shares
Shares Outstanding: 164.88 (millions)
Market Capitalization: $82.75 (millions)
Beta: 1.28
52 Week High: $9.86
52 Week Low: $0.44
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.11% -23.42%
12 Week -67.41% -64.64%
Year To Date -79.92% -76.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 TECHNOLOGY SQUARE
-
CAMBRIDGE,MA 02139
USA
ph: 617-229-5872
fax: 617-349-0707
wslattery@w2ogroup.com http://www.epizyme.com
 
 • General Corporate Information   
Officers
Robert B. Bazemore - President and Chief Executive Officer
Paolo Tombesi - Chief Financial Officer
Joseph Beaulieu - Corporate Controller and Treasurer
Andrew R. Allen - Director
Kenneth Bate - Director

Peer Information
Epizyme, Inc. (CORR.)
Epizyme, Inc. (RSPI)
Epizyme, Inc. (CGXP)
Epizyme, Inc. (BGEN)
Epizyme, Inc. (GTBP)
Epizyme, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29428V104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 164.88
Most Recent Split Date: (:1)
Beta: 1.28
Market Capitalization: $82.75 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 2.15
EPS Growth
vs. Year Ago Period: 43.48%
vs. Previous Quarter: 20.41%
Sales Growth
vs. Year Ago Period: 13.96%
vs. Previous Quarter: -24.92%
ROE
03/31/22 - -
12/31/21 - -2,459.33
09/30/21 - -432.91
ROA
03/31/22 - -73.85
12/31/21 - -72.76
09/30/21 - -68.16
Current Ratio
03/31/22 - 5.87
12/31/21 - 4.56
09/30/21 - 5.53
Quick Ratio
03/31/22 - 5.75
12/31/21 - 4.49
09/30/21 - 5.50
Operating Margin
03/31/22 - -616.85
12/31/21 - -671.02
09/30/21 - -779.45
Net Margin
03/31/22 - -614.08
12/31/21 - -671.02
09/30/21 - -779.45
Pre-Tax Margin
03/31/22 - -613.94
12/31/21 - -670.91
09/30/21 - -779.12
Book Value
03/31/22 - -0.15
12/31/21 - -0.54
09/30/21 - -0.20
Inventory Turnover
03/31/22 - 3.95
12/31/21 - 2.04
09/30/21 - 1.32
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - 95.12
12/31/21 - -
09/30/21 - 93.36
 

Powered by Zacks Investment Research ©